The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

New England Journal of Medicine

Volumn 338, Issue 10, 1998, Pages 645-652

  Estacio, Raymond O ^a,b,e   Jeffers, Barrett W ^a,c   Hiatt, William R ^a,d,e   Biggerstaff, Stacy L ^a   Gifford, Nancy ^a,c   Schrier, Robert W ^a,c  

^a Colorado Prevention Center ^*

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Division of Genatrics

^d Vascular Surgery Section   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; ENALAPRIL MALEATE; NISOLDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NISOLDIPINE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032485350     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199803053381003     Document Type: Article

References (38)

1. National Center for Health Statistics. Advance report of final mortality statistics, 1986. Mon Vital Stat Rep 1988;37(6):Suppl:1-56.
2. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123-31. [Erratum, Diabetologia 1987;30:364.]
3. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123-31. [Erratum, Diabetologia 1987;30:364.]
4. Moss SE, Klein R, Klein BE. Cause-specific mortality in a populationbased study of diabetes. Am J Public Health 1991;81:1158-62.
5. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial: the SAVE Investigators. N Engl J Med 1992;327:669-77.
6. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitirate, and intravenous magnesium sulphate in 58 050 patients with suspected acute my our dial infarction. Lancet 1995;345:669-85.
7. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinupril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Mod 1987;316:1429-35.
9. The SOLVD Investigators, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med 1992;327:685-91.
10. Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-8.
11. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995;155:829-37.
12. Parving HH. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabetes Complications 1996;10:133-5.
13. Lewis EJ. Angiotensin-converting enzyme inhibition in type I diabetic nephropathy. Contrib Nephrol 1996;118:206-13.
14. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
15. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotonsin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996;156:286-9.
16. Parving HH, Rossing P, Hummel E, Smidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995;26:99-107.
17. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
18. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
19. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS); a randomized controlled trial. JAMA 1996;276:785-91.
20. Savage S, Johnson Nagel N, Estacio RO, et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online J Curr Clin Trials 1993 Nov 24;Doc. No. 104:[6250 words; 128 paragraphs].
21. Diabetes mellitus: report of a WHO study group. WHO Tech Rep Ser 1985;727:7-113.
22. Heyden S, Bartel AG, Tabesh E, et al. Angina pectoris and the Rose questionnaire. Arch Intern Med 1971;128:961-4.
23. Hiatt WR, Marshall JA, Baxter J, et al. Diagnostic methods for peripheral arterial disease in the San Luis Valley Diabetes Study. J Clin Epidemiol 1990;43:597-606.
24. Estacio RO, Savage S, Nagel NJ, Schrier RW. Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial. Control Clin Trials 1996;17:242-57.
25. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology 1991;98:Suppl:786-806.
26. Report and recommendations of the San Antonio conference on diabetic neuropathy. Ann Neurol 1988;24:99-104.
27. Mogensen CE. Microalbuminuria in diabetic renal disease. In: Mogensen CE, Standl E, eds. Prevention and treatment of diabetic late complications. New York: Walter de Gruyter, 1989:41-73.
28. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977;55:613-8.
29. Kornitzer M, Dramaix M, Sobolski J, Degre S, De Backer G, Ankle/ arm pressure index in asymptomatic middle-aged males: an independent predictor of ten-year coronary heart disease mortality. Angiology 1995;46: 211-9.
30. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991;87: 119-28.
31. Glasser SP, Ripa S, Garland WT, et al. Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina. J Clin Pharmacol 1995;35:780-4.
32. Heublein B, Amende I, Blanke PM, Baunack-Frost AR, Breuer HW. Nisoldipine versus isosorbide dinitrate in coronary heart disease: result of a double-masked study. Clin Ther 1996;18:448-59.
33. Weinstein DB, Heider JG. Protective action of calcium channel antagonists in atherogenesis and experimental vascular injury. Am J Hypertens 1989;2:205-12.
34. Lichtien PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jose S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335:1109-13.
35. Waters D, Lesperance J. Interventions that beneficially influence the evolution of coronary atherosclerosis: the case for calcium channel blockers. Circulation 1992;86:SuppI III:III-111-III-116.
36. Janka HU, Dirschedl P. Systolic blood pressure as a predictor for cardiovascular disease in diabetes: a 5-year longitudinal study. Hypertension 1985;7:II-90-II-94.
37. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.
38. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7.